No Data
Stocks that moved the previous day part 1: Business Coach, Musashi Seimitsu Industry, Toyota Motor, ETC.
Stock Name <Code> Closing price on the 26th ⇒ Comparison with the previous day. Aresti <5852> 605 +18 Introduced a Shareholder benefit program. Nifco <7988> 3868 +124 Announced a Share Buyback of up to 0.60% of the issued Stocks. Towns <197A> 591 +52 Reached a basic agreement on a Trade contract with Roche Diagnostics. Stella Chemifa <4109> 4250 +170 Operating results for the fiscal year ending March 2025.
The Tokyo Stock Exchange Growth Index continued to rise slightly, fluctuating within the positive range, but the increase was limited.
TSE Growth Market Index 807.85 +0.83 / Volume 0.2 billion 8.3 million shares / Transaction value 141.4 billion yen TSE Growth Market 250 Index 632.16 +0.70 / Volume 0.1 billion 14.88 million shares / Transaction value 100.2 billion yen Today's growth market shows that the TSE Growth Market Index and TSE Growth Market 250 Index both saw slight increases, with 282 rising stocks, 291 declining stocks, and 31 unchanged. Today's growth market had a heavy outlook.
Afternoon session [Active stocks and traded stocks]
*Aresti <5852> 605 +18 Introduced a shareholder benefit program. *Nihon Hume <5262> 1395 +46 Changed and expanded the shareholder benefit program. *Nifco <7988> 3868 +124 Announced a Share Buyback with a limit of 0.60% of the issued Stocks. *Towns <197A> 591 +52 Reached a basic agreement on a trade contract with Roche Diagnostics. *Stella Chemifa <4109> 4250 +170 Financial Estimates for the fiscal year ending March 2025 and mid-term management plan numbers.
Emerging Markets Stock Digest: Synbio Pharmaceuticals continues to fall, Business Coach temporarily hits the upper limit.
＜4263＞ Susmed 582 +7 rebound. It was announced that the operation of a clinical trial system (SUSMED SDS) utilizing Blockchain Technology was started in a doctor-led clinical trial at the National Center of Neurology and Psychiatry. This clinical trial targets patients with myalgic encephalomyelitis/chronic fatigue syndrome, aiming to verify the efficacy and safety of Rituximab. Utilizing SUSMED SDS, it aims to reduce monitoring tasks and improve the quality and reliability of the data obtained.
Business Coach: Confirmation
Business Coach: Financial Report - 20th Term (2023/10/01 - 2024/09/30)
No Data